Arrowhead Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arrowhead Pharma (ARWR).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

12Buy

3Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$89Upside to Avg. PT+52.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	John Lee	Assumes	Buy	$63→$109
Oct 15, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$115
Oct 15, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$120
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Neutral	$74
Sep 8, 2026	Citigroup	Eric Joseph	Initiate	Buy	$108
Sep 1, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$120
Aug 31, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$115
Aug 31, 2026	RBC Capital	Luca Issi	Maintained	Outperform	$100
Aug 6, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$115→$120
Jul 30, 2026	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$101→$123
Jul 27, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$100→$115
Jul 23, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$100→$120
Jul 23, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$110→$126
Jul 22, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$90→$115
Jul 17, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$88→$95
Jul 14, 2026	Stifel	James Condulis	Initiate	Buy	$98
Jul 1, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$100
Jun 30, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$90
Jun 17, 2026	Leerink Partners	Mani Foroohar	PT Raise	Market Perform	$61→$72
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$35→$46

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.

Benzinga Newsdesk

Arrowhead Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

Arrowhead Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PROGoldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PROCitigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRORBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PROHC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120